{"entity":{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","aka":[],"tldr":"Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.","summary":"Oliver Sartor was co-principal investigator of VISION, which showed 177Lu-PSMA-617 improves survival in PSMA-positive metastatic castration-resistant prostate cancer and led to Pluvicto's approval, and was a lead investigator of PSMAfore, which moved the therapy before chemotherapy. He also co-led ALSYMPCA (radium-223). He directs the radiopharmaceutical trials programme at Mayo Clinic.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Oliver_Sartor","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium"}],"tags":["prostate","radioligand","trialist"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["radioligand-therapy","psma-pet"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":["vision","psmafore","alsympca"],"people":[],"bottlenecks":[],"keyPapers":["paper-vision-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology and Urology, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Prostate cancer","Radioligand therapy","PSMA-targeted therapy","Radium-223"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium"}],"papers":[{"title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2107322"},{"title":"Alpha emitter radium-223 and survival in metastatic prostate cancer (ALSYMPCA)","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1213755"}]},"route":"/people/oliver-sartor/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"drug":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"institution":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/"}],"trial":[{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/"},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/"},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/"}],"paper":[{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/"}]}}